B. 1. Jabs, D. Nussenblatt, R. Rosenbaum, and J. , Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, Am J Ophthalmol, vol.140, issue.3, pp.509-525, 2005.

D. Smet, M. Okada, and A. , Cystoid Macular Edema in Uveitis, Dev Ophthalmol, vol.47, pp.136-183, 2010.
DOI : 10.1159/000320077

D. Wakefield and J. Chang, Epidemiology of Uveitis, International Ophthalmology Clinics, vol.45, issue.2, pp.1-13, 2005.
DOI : 10.1097/01.iio.0000155938.83083.94

D. Kozak, Y. Sakai, J. Thillaye, B. Faure, and J. , S antigen-induced experimental autoimmune uveo-retinitis in rats, Current Eye Research, vol.101, issue.6, pp.327-364, 1981.
DOI : 10.3109/02713688108998359

E. Carswell, L. Old, R. Kassel, S. Green, N. Fiore et al., An endotoxininduced serum factor that causes necrosis of tumors, Proc Natl Acad Sci, 1975.

S. Nakamura, T. Yamakawa, M. Sugita, M. Kijima, M. Ishioka et al., The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice, Invest Ophthalmol Vis Sci, vol.35, issue.11, pp.3884-3893, 1994.

N. Derevjanik, S. Vinores, W. Xiao, K. Mori, T. Turon et al., Quantitative assessment of the integrity of the blood-retinal barrier in mice, Invest Ophthalmol Vis Sci, vol.43, issue.7, pp.2462-2469, 2002.

S. Lacomba, M. , M. Martín, C. , G. Galera et al., Aqueous Humor and Serum Tumor Necrosis Factor-?? in Clinical Uveitis, Ophthalmic Research, vol.33, issue.5, pp.251-256, 2001.
DOI : 10.1159/000055677

M. Robertson, J. Liversidge, J. Forrester, A. Dick, A. Dick et al., Neutralizing Tumor Necrosis Factor-?? Activity Suppresses Activation of Infiltrating Macrophages in Experimental Autoimmune Uveoretinitis, Investigative Opthalmology & Visual Science, vol.44, issue.7, pp.3034-3075, 2003.
DOI : 10.1167/iovs.02-1156

M. Hangai, S. He, S. Hoffmann, J. Lim, S. Ryan et al., Sequential induction of angiogenic growth factors by TNF-?? in choroidal endothelial cells, Journal of Neuroimmunology, vol.171, issue.1-2, pp.45-56, 2006.
DOI : 10.1016/j.jneuroim.2005.09.018

M. Cordero-coma, V. Calvo-río, A. Adán, R. Blanco, C. Álvarez-castro et al., Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis, Mediators Inflamm. J Ophthalmic Inflamm Infect, vol.2014, pp.717598-717614, 2012.

E. Miserocchi, G. Modorati, I. Pontikaki, P. Meroni, V. Gerloni et al., Long-term treatment with golimumab for severe uveitis Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series, Ocul Immunol Inflamm. 2014 Clin Experiment Ophthalmol, vol.2242, issue.24, pp.90-95, 2014.

V. Perez, J. Hammel, and C. Lowder, Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease Arthritis Rheum Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation, Ophthalmology, vol.45, issue.3, pp.252-259, 2001.

T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson et al., Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006.
DOI : 10.1001/jama.295.19.2275

C. Roux, O. Brocq, V. Breuil, C. Albert, and L. Euller-ziegler, Safety of anti-TNF-?? therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis, Rheumatology, vol.45, issue.10, pp.1294-1301, 2006.
DOI : 10.1093/rheumatology/kel123

J. Sellam, B. Bouvard, C. Masson, M. Rousière, C. Villoutreix et al., Use of infliximab to treat psoriatic arthritis in HIV-positive patients, Joint Bone Spine, vol.74, issue.2, 2007.
DOI : 10.1016/j.jbspin.2006.05.012

V. Williams and P. Cohen, TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists, International Journal of Dermatology, vol.22, issue.5, pp.619-644, 2011.
DOI : 10.1111/j.1365-4632.2011.04871.x

C. Mercieca, N. Vella, and A. Borg, Demyelination during anti-TNF?? therapy for ankylosing spondylitis, Modern Rheumatology, vol.70, issue.1, pp.303-310
DOI : 10.1001/archneurol.2009.11

N. Berghen, L. Teuwen, R. Westhovens, and P. Verschueren, Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study, Backhouse OC. Does etanercept induce uveitis, 2003.
DOI : 10.1007/s10067-015-3026-7

E. Chung, M. Packer, K. Lo, A. Fasanmade, J. Willerson et al., Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebocontrolled , pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factoralpha , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders A pilot study of normative data for macular thickness and volume measurements using cirrus high-definition optical coherence tomography, Ophthalmology. Retina, vol.8710712131, issue.3139, pp.9253133-40785, 2003.

V. Goëb, M. Ardizzone, L. Arnaud, J. Avouac, A. Baillet et al., Recommendations for using TNF?? antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health, Joint Bone Spine, vol.80, issue.6, 2013.
DOI : 10.1016/j.jbspin.2013.09.001

J. Martel, E. Esterberg, A. Nagpal, and N. Acharya, Infliximab and Adalimumab for Uveitis, Ocular Immunology and Inflammation, vol.18, issue.6, pp.18-26, 2012.
DOI : 10.1136/bmj.b2480

E. Suhler, J. Smith, M. Wertheim, A. Lauer, D. Kurz et al., A Prospective Trial of Infliximab Therapy for Refractory Uveitis, Archives of Ophthalmology, vol.123, issue.7, pp.903-915, 2005.
DOI : 10.1001/archopht.123.7.903

K. Kam, L. Tam, M. Tam, A. Young, R. Lopez-gonzalez et al., Infliximab in the treatment of refractory ocular inflammatory diseases 2015 Feb Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study Infliximab for the treatment of refractory noninfectious Uveitis: a study of 88 patients with long-term follow-up, Asia Pac J Ophthalmol (Phila) Scand J Rheumatol. Feb Kruh JN, vol.438, issue.38, pp.19-2458, 2009.

M. Díaz-llopis, D. Salom, C. Garcia-de-vicuña, M. Cordero-coma, G. Ortega et al., Treatment of Refractory Uveitis with Adalimumab: A Prospective Multicenter Study of 131 Patients, Ophthalmology, vol.119, issue.8, pp.1575-81, 2012.
DOI : 10.1016/j.ophtha.2012.02.018

B. Dobner, R. Max, M. Becker, C. Heinz, I. Veltrup et al., A three-centre experience with adalimumab for the treatment of non-infectious uveitis, British Journal of Ophthalmology, vol.97, issue.2, pp.134-142, 2013.
DOI : 10.1136/bjophthalmol-2011-301401

A. Arida, K. Fragiadaki, E. Giavri, P. Sfikakis, L. Niccoli et al., Anti-TNF agents for Behçet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum Longterm efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study, Rheumatology, vol.4146, issue.17, pp.61-70, 2007.

F. Cantini, L. Niccoli, C. Nannini, O. Kaloudi, E. Cassarà et al., Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients, Biologics, vol.6, pp.5-12, 2012.

P. Artornsombudh, O. Gevorgyan, A. Payal, S. Siddique, and C. Foster, Infliximab Treatment of Patients with Birdshot Retinochoroidopathy, Ophthalmology, vol.120, issue.3, p.2013
DOI : 10.1016/j.ophtha.2012.05.048

L. Riancho-zarrabeitia, V. Calvo-río, R. Blanco, M. Mesquida, A. Adan et al., Anti-TNF-? therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients Anti-TNF-alpha therapy for sight threatening uveitis, Semin Arthritis Rheum Br J Ophthalmol, vol.4889, issue.5, pp.533-539, 2005.

A. Journal, M. Ophthalmologyfogler, R. Amer, R. Friling, E. Priel et al., Anti-TNF-? agents for refractory cystoid macular edema associated with noninfectious uveitis, Graefes Arch Clin Exp Ophthalmol. 2014, vol.138252, issue.504, pp.648-50633, 2004.

L. Sobrin, E. Kim, C. W. Papadaki, T. Letko, E. Foster et al., Infliximab Therapy for the Treatment of Refractory Ocular Inflammatory Disease, Archives of Ophthalmology, vol.125, issue.7, pp.895-900, 2007.
DOI : 10.1001/archopht.125.7.895

E. Lindstedt, G. Baarsma, R. A. Kuijpers, V. Hagen, and P. , Anti-TNF-?? therapy for sight threatening uveitis, British Journal of Ophthalmology, vol.89, issue.5, pp.533-539, 2005.
DOI : 10.1136/bjo.2003.037192

R. Ordás-calvo and C. , Resolution of refractory uveitis, switching anti-TNF treatment. Reumatol Clin, pp.379-80, 2012.

N. Dhingra, J. Morgan, and A. Dick, Switching biologic agents for uveitis, Eye, vol.31, issue.9
DOI : 10.1038/eye.2009.203

P. Durez, J. Malghem, A. Toukap, G. Depresseux, B. Lauwerys et al., Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone, Arthritis & Rheumatism, vol.41, issue.12, pp.3919-3946, 2007.
DOI : 10.1002/art.23055

J. Colombel, W. Sandborn, W. Reinisch, G. Mantzaris, A. Kornbluth et al., Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-95, 2010.
DOI : 10.1056/NEJMoa0904492

E. Suhler, J. Smith, T. Giles, A. Lauer, M. Wertheim et al., Infliximab therapy for refractory uveitis: 2-year results of a prospective trial, Arch Ophthalmol, 2009.

B. Dobner, R. Max, M. Becker, C. Heinz, I. Veltrup et al., A threecentre experience with adalimumab for the treatment of non-infectious uveitis, Br J Ophthalmol. 2013 Feb, vol.197, issue.2, pp.134-142

L. Chen and L. Gordon, Ocular manifestations of multiple sclerosis, Current Opinion in Ophthalmology, vol.16, issue.5, pp.315-335, 2005.
DOI : 10.1097/01.icu.0000179804.49842.e2

J. Kempen, S. Gangaputra, E. Daniel, G. Levy-clarke, R. Nussenblatt et al., Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence, e1. 62. Cordero-Coma M, Sobrin L. Anti-Tumor Necrosis Factor-? Therapy in Uveitis, pp.802-812, 2008.
DOI : 10.1016/j.ajo.2008.04.035

K. Mckeage, A Review of CT-P13: An Infliximab Biosimilar, BioDrugs, vol.10, issue.4, p.2014
DOI : 10.1007/s40259-014-0094-1

L. Costa, Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review, Clin Exp Rheumatol, vol.32, issue.4, pp.54-57, 2014.

G. Simonini, R. Cimaz, G. Jones, G. Macfarlane, S. Sugita et al., Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: The current evidence from a systematic review Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease, Semin Arthritis Rheum Br J Ophthalmol, vol.6695, issue.4, pp.549-52, 2011.

M. Farvardin, M. Afarid, and S. Shahrzad, Long-Term Effects of Intravitreal Infliximab for Treatment of Sight Threatening Chronic Noninfectious Uveitis, Journal of Ocular Pharmacology and Therapeutics, 2012.
DOI : 10.1089/jop.2011.0199

N. Markomichelakis, E. Delicha, S. Masselos, and P. Sfikakis, Intravitreal Infliximab for Sight-Threatening Relapsing Uveitis in Beh??et Disease: A Pilot Study in 15 Patients, American Journal of Ophthalmology, vol.154, issue.3, pp.534-541
DOI : 10.1016/j.ajo.2012.03.035

G. Mollayess, Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study, Ocul Immunol Inflamm, pp.1-8, 2015.

. Adalimumab, Les patients non répondeurs ou ayant présenté une récidive inflammatoire dans les 3 premiers mois étaient donc tous traités par Adalimumab En tenant compte de l'étiologie, étaient contrôlés 100,0% des patients atteints d'une maladie de Behçet (N=7), 100% des patients atteints d'une maladie de Birdshot (N=3), 100% des patients atteints d'une sarcoïdose (N=2), et 55, 5% des patients atteints d'uvéites idiopathiques et autres (N=5) (figures 3

D. Jabs and J. Rosenbaum, Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel, American Journal of Ophthalmology, vol.131, issue.5, p.679, 2001.
DOI : 10.1016/S0002-9394(01)00830-3

E. Carswell, L. Old, R. Kassel, S. Green, N. Fiore et al., An endotoxininduced serum factor that causes necrosis of tumors, Proc Natl Acad Sci, 1975.

S. Nakamura, T. Yamakawa, M. Sugita, M. Kijima, M. Ishioka et al., The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice, Invest Ophthalmol Vis Sci, vol.35, issue.11, pp.3884-3893, 1994.

S. Lacomba, M. , M. Martín, C. , G. Galera et al., Aqueous Humor and Serum Tumor Necrosis Factor-?? in Clinical Uveitis, Ophthalmic Research, vol.33, issue.5, pp.251-256, 2001.
DOI : 10.1159/000055677

M. Robertson, J. Liversidge, J. Forrester, and A. Dick, Neutralizing Tumor Necrosis Factor-?? Activity Suppresses Activation of Infiltrating Macrophages in Experimental Autoimmune Uveoretinitis, Investigative Opthalmology & Visual Science, vol.44, issue.7, pp.3034-3075, 2003.
DOI : 10.1167/iovs.02-1156

C. Murphy, W. Ayliffe, A. Booth, D. Makanjuola, P. Andrews et al., Tumor necrosis factor ?? blockade with infliximab for refractory uveitis and scleritis, Ophthalmology, vol.111, issue.2, pp.352-358, 2004.
DOI : 10.1016/S0161-6420(03)00721-8

D. Jabs, R. Nussenblatt, and J. Rosenbaum, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop, Am J Ophthalmol, vol.140, issue.3, pp.509-525, 2005.

J. Martel, E. Esterberg, A. Nagpal, and N. Acharya, Infliximab and Adalimumab for Uveitis, Ocular Immunology and Inflammation, vol.18, issue.6, pp.18-26, 2012.
DOI : 10.1136/bmj.b2480

K. Kam, L. Tam, M. Tam, A. Young, J. Kruh et al., Infliximab in the Treatment of Refractory Ocular Inflammatory Diseases, Asia-Pacific Journal of Ophthalmology, vol.4, issue.1, pp.19-24, 2014.
DOI : 10.1097/APO.0000000000000036

R. Lopez-gonzalez, E. Loza, J. Jover, B. D. Castillo, J. Mendez et al., Treatment of refractory posterior uveitis with infliximab: a 7???year follow???up study, Scandinavian Journal of Rheumatology, vol.46, issue.1, pp.58-62, 2009.
DOI : 10.1001/archopht.123.7.903

J. Martel, E. Esterberg, A. Nagpal, A. Nrllopis, M. Salom et al., Infliximab and adalimumab for uveitis Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients, Ocul Immunol Inflamm. 2012 Feb; Ophthalmology, vol.20119, issue.148, pp.18-261575, 2012.

B. Dobner, R. Max, M. Becker, C. Heinz, I. Veltrup et al., A three-centre experience with adalimumab for the treatment of non-infectious uveitis, British Journal of Ophthalmology, vol.97, issue.2, pp.134-142, 2013.
DOI : 10.1136/bjophthalmol-2011-301401

D. Morris, M. Gavin, and R. Sturrock, The Effect of Anti-Tumour Necrosis Factor alpha (Infliximab) on Sight-Threatening Uveitis in a Patient with Beh??et???s Disease, Adv Exp Med Biol, vol.528, pp.557-566, 2003.
DOI : 10.1007/0-306-48382-3_112

L. Niccoli, C. Nannini, M. Benucci, D. Chindamo, E. Cassarà et al., Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study, Rheumatology, vol.46, issue.7, pp.1161-1165, 2007.
DOI : 10.1093/rheumatology/kem101

F. Cantini, L. Niccoli, C. Nannini, O. Kaloudi, E. Cassarà et al., Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients, Biologics. Perra D, vol.6, issue.20, pp.5-12, 2012.

V. Río, R. Blanco, E. Beltrán, J. Sánchez-bursón, M. Mesquida et al., Adalimumab for the treatment of Behçet's disease: experience in 19 patients Rheumatology (Oxford), pp.1825-1856, 2012.

M. Takeuchi, T. Kezuka, S. Sugita, H. Keino, K. Namba et al., Evaluation of the Long-Term Efficacy and Safety of Infliximab Treatment for Uveitis in Beh??et's Disease, Ophthalmology, vol.121, issue.10, pp.1877-84, 2014.
DOI : 10.1016/j.ophtha.2014.04.042

A. Okada, H. Goto, S. Ohno, and M. Mochizuki, Ocular Behçet's Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease, Arch Ophthalmol. 2012, vol.130, issue.5, pp.592-600

E. Interlandi, P. Leccese, I. Olivieri, and L. Latanza, Adalimumab for treatment of severe Behçet's uveitis: a retrospective long-term follow-up study, Clin Exp Rheumatol, 2014.

A. Levy-clarke, G. Jabs, D. Read, R. Rosenbaum, J. Vitale et al., Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders Infliximab treatment of patients with birdshot retinochoroidopathy, Rheumatology. Ophthalmology. Artornsombudh P Ophthalmology, vol.46121, issue.263, pp.736-41785, 2007.

V. Menezo and S. Taylor, Birdshot uveitis: current and emerging treatment options, Clin Ophthalmol, vol.8, pp.73-81, 2014.

L. Riancho-zarrabeitia, V. Calvo-río, R. Blanco, M. Mesquida, A. Adan et al., Anti-TNF-? therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients Anti-TNF-alpha therapy for sight threatening uveitis, Semin Arthritis Rheum Br J Ophthalmol, vol.3089, issue.5, pp.533-539, 2005.

M. Hangai, S. He, S. Hoffmann, J. Lim, S. Ryan et al., Sequential induction of angiogenic growth factors by TNF-?? in choroidal endothelial cells, Journal of Neuroimmunology, vol.171, issue.1-2, pp.45-56, 2006.
DOI : 10.1016/j.jneuroim.2005.09.018

A. Journal, M. Ophthalmologyfogler, R. Amer, R. Friling, E. Priel et al., Anti-TNF-? agents for refractory cystoid macular edema associated with noninfectious uveitis, Graefes Arch Clin Exp Ophthalmol. 2014, vol.138252, issue.334, pp.648-50633, 2004.

P. Durez, J. Malghem, A. Toukap, G. Depresseux, B. Lauwerys et al., Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone, Arthritis & Rheumatism, vol.41, issue.12, pp.3919-3946, 2007.
DOI : 10.1002/art.23055

J. Colombel, W. Sandborn, W. Reinisch, G. Mantzaris, A. Kornbluth et al., Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease, New England Journal of Medicine, vol.362, issue.15, pp.1383-95, 2010.
DOI : 10.1056/NEJMoa0904492

N. Dhingra, J. Morgan, and A. Dick, Switching biologic agents for uveitis, Eye, vol.31, issue.9
DOI : 10.1038/eye.2009.203

T. Bongartz, A. Sutton, M. Sweeting, I. Buchan, E. Matteson et al., Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006.
DOI : 10.1001/jama.295.19.2275

C. Roux, O. Brocq, V. Breuil, C. Albert, and L. Euller-ziegler, Safety of anti-TNF-?? therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis, Rheumatology, vol.45, issue.10, pp.1294-1301, 2006.
DOI : 10.1093/rheumatology/kel123

C. Mercieca, N. Vella, and A. Borg, Demyelination during anti-TNF?? therapy for ankylosing spondylitis, Modern Rheumatology, vol.70, issue.1, pp.303-310
DOI : 10.1001/archneurol.2009.11

N. Berghen, L. Teuwen, R. Westhovens, P. Verschueren, E. Suhler et al., Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes, Clin Rheumatol Arch Ophthalmol, vol.41123, issue.7, pp.903-915, 2005.

E. Suhler, J. Smith, T. Giles, A. Lauer, M. Wertheim et al., Infliximab therapy for refractory uveitis: 2-year results of a prospective trial, Arch Ophthalmol, 2009.

L. Chen and L. Gordon, Ocular manifestations of multiple sclerosis, Current Opinion in Ophthalmology, vol.16, issue.5, pp.315-335, 2005.
DOI : 10.1097/01.icu.0000179804.49842.e2

M. Cordero-coma and L. Sobrin, Anti???tumor necrosis factor-?? therapy in uveitis, Survey of Ophthalmology, vol.60, issue.6, 2015.
DOI : 10.1016/j.survophthal.2015.06.004